| Literature DB >> 20473904 |
Elena Kashuba1, Mariya Yurchenko, Surya Pavan Yenamandra, Boris Snopok, Laszlo Szekely, Beatrice Bercovich, Aaron Ciechanover, George Klein.
Abstract
We report that MDM2, a negative regulator of p53, can bind to EBNA-5. Using GST pull-down assay, immunoprecipitation, surface plasmon resonance and immunostaining of lymphoblastoid cells, we found that trimolecular complexes are formed between EBNA-5, MDM2 and p53, where MDM2 serves as a bridge. The EBNA-5 binding to MDM2 counteracted destabilizing effect of the latter on the p53. In ubiquitination and degradation assays in vitro, EBNA-5 inhibited p53 polyubiquitination (but not monoubiquitination) in a concentration-dependent manner. This resembles the effect of p14ARF on p53. Moreover, EBNA-5 was found to inhibit the degradation of p53 in vitro. High levels of p53 expression were maintained in LCLs. The binding of EBNA-5 to MDM2 also could impair the functional activity of p53. The p53-dependent genes P21 and VDR were not induced in EBV-infected, in contrast to mitogen-activated cells. This may explain the tolerance of established LCLs to high levels of p53 without undergoing apoptosis.Entities:
Mesh:
Substances:
Year: 2011 PMID: 20473904 DOI: 10.1002/ijc.25414
Source DB: PubMed Journal: Int J Cancer ISSN: 0020-7136 Impact factor: 7.396